On Friday, Calidi Biotherapeutics Inc (AMEX: CLDI) opened lower -9.46% from the last session, before settling in for the closing price of $1.48. Price fluctuations for CLDI have ranged from $0.73 to $16.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -50.00%. Company’s average yearly earnings per share was noted 78.64% at the time writing. With a float of $16.77 million, this company’s outstanding shares have now reached $93.11 million.
The extent of productivity of a business whose workforce counts for 41 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Calidi Biotherapeutics Inc (CLDI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Calidi Biotherapeutics Inc is 11.04%, while institutional ownership is 1.63%. The most recent insider transaction that took place on Dec 17 ’24, was worth 16,200. In this transaction CEO and Chairman of the Board of this company sold 10,000 shares at a rate of $1.62, taking the stock ownership to the 66,712 shares.
Calidi Biotherapeutics Inc (CLDI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 78.64% per share during the next fiscal year.
Calidi Biotherapeutics Inc (AMEX: CLDI) Trading Performance Indicators
Check out the current performance indicators for Calidi Biotherapeutics Inc (CLDI). In the past quarter, the stock posted a quick ratio of 0.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.81, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Calidi Biotherapeutics Inc (CLDI)
The latest stats from [Calidi Biotherapeutics Inc, CLDI] show that its last 5-days average volume of 1.07 million was superior to 0.52 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 24.35%. Additionally, its Average True Range was 0.22.
During the past 100 days, Calidi Biotherapeutics Inc’s (CLDI) raw stochastic average was set at 19.30%, which indicates a significant increase from 8.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.44% in the past 14 days, which was lower than the 158.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6966, while its 200-day Moving Average is $2.1198. Now, the first resistance to watch is $1.4402. This is followed by the second major resistance level at $1.5404. The third major resistance level sits at $1.6005. If the price goes on to break the first support level at $1.2799, it is likely to go to the next support level at $1.2198. The third support level lies at $1.1196 if the price breaches the second support level.
Calidi Biotherapeutics Inc (AMEX: CLDI) Key Stats
There are currently 13,078K shares outstanding in the company with a market cap of 22.87 million. Presently, the company’s annual sales total 0 K according to its annual income of -29,220 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -5,070 K.
